Please login to the form below

Not currently logged in
Email:
Password:

Ipsen reports profit increase

Ipsen has revealed a rise in profit and sales for the first half of 2011

Ipsen, the French pharmaceutical company, has reported a 21 per cent increase in consolidated net profit to €91.7m in the first half of 2011.

The group's consolidated sales were €583.1m, an increase of 5 per cent on the same period of 2010. Sales were driven by its neurology and endocrinology franchises, and the resilience of its primary care drugs.

Marc de Garidel, chairman and chief executive, said: "Since the announcement of the new strategy on June 9, Ipsen has been gearing up to fulfill its 2020 ambition. To this end, all the positions in the group's executive committee have now been filled and the administrative and employee-related procedures required for authorisation to close the Barcelona R&D site have been completed.

"In Europe, we have just entered into an agreement in haemophilia with our partner Inspiration Biopharmaceuticals to build a strong commercial presence. Lastly, in North America, we began transferring our commercial activities to the east coast. Now that we have laid down the foundations in our vision, we will introduce in the coming months the investments announced on June 9," he added.

The company's R&D expenses increased by 7 per cent to €105.8m in the six month period.

31st August 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Lucid Group Communications Limited

WE’RE ON A MISSION To enhance patients’ lives through communication that changes behaviour and improves patient health outcomes....

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics